https://www.grandviewresearch.com/press-release/global-duchenne-muscular-dystrophy-dmd-drugs-market
Mutation-specific therapies, such as Translarna, are anticipated to face limited adoption due to premium pricing.
Associated adverse effects of steroid therapy make them a less favored treatment option
Mutation -suppressive therapeutics and steroids are projected to witness healthy growth due to increasing adoption of Translarna and EmflazaTranslarna received conditional approval in Europe in 2014 for the treatment of nonsense mutation DMD patients who are in ambulatory state and are 5 years or older. Exondys51 and Emflaza have not been approved for DMD treatment in Europe
I remember CG talking about steroids being nasty
and Clinicians don’t like using them
Heres a chance for ATL1102 to shine $$
Where is everyone ? Very exciting next 8 weeks
$5 in time
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-351
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.3¢ |
Change
-0.002(2.67%) |
Mkt cap ! $65.81M | |||
| Open | High | Low | Value | Volume |
| 7.5¢ | 7.5¢ | 7.3¢ | $31.44K | 421.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 661162 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 120000 | 1 |
View Market Depth
| Last trade - 15.59pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
-0.002 ( 1.33 %) |
||||
| Open | High | Low | Volume | ||
| 7.4¢ | 7.4¢ | 7.4¢ | 14050 | ||
| Last updated 14.59pm 23/05/2024 ? | |||||
| PER (ASX) Chart |